ClinicalTrials.gg
RecruitingNCT03663348Updated Nov 17, 2026

Registry of Patients With Takotsubo Syndrome

An observational study in Takotsubo Cardiomyopathy, Broken Heart Syndrome and Tako-tsubo Cardiomyopathy, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NYU Langone Health · Observational

How we know

From the registry’s dates

  • Started Sep 2009; still recruiting 17 years 2 months later.
Updated Nov 17, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Takotsubo Cardiomyopathy with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Takotsubo Cardiomyopathy · United States.

Started
2009
with 1 other
Observational
5 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
2 of 11
NYU Langone Health

Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, this one is one of 2 that started in 2009, is one of 5 observational ones, and was the 7th registered.

Takotsubo Cardiomyopathy

63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.

Browse Takotsubo Cardiomyopathy studies →

Open to participants now

3 of the 11 studies in Takotsubo Cardiomyopathy with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Takotsubo Cardiomyopathy studies recruiting now, 19 (83%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Takotsubo Cardiomyopathy with a site in United States, or all of them as a file.
02

Study summary

Takotsubo syndrome is a condition which mimics acute myocardial infarction, and is diagnosed in 1.5% to 2.2% of patients referred to hospital with suspected acute coronary syndrome. It is also known as broken heart syndrome, takotsubo cardiomyopathy, stress cardiomyopathy and apical ballooning cardiomyopathy, among other names. The pathogenesis of this disorder is not well understood. Possible mechanisms include catecholamine excess, coronary artery spasm, microvascular dysfunction, among others. This is a multicenter, nation-wide, observational study of patients who were previously diagnosed with takotsubo syndrome. The investigators aim to use this registry to help plan and carry out further studies and to improve understanding of the pathophysiologic mechanisms of this syndrome. In addition participants will be followed for events, and to monitor quality of life and stress.

Read the detailed description

Patients are eligible to participate if they are aged 18 years or older and carry a physician confirmed diagnosis of takotsubo syndrome. Patients with a history of takotsubo syndrome will be identified via physician referral, Epic search and patient self-referral. Patients may register directly through our registry website at www.nyulmc.org/brokenheartstudy or via direct contact with the study team via e-mail or telephone. Following completion of a research authorization form and collection of medical records, study team will confirm the diagnosis of takotsubo syndrome. Data will be collected including contact information, medical history, data on the takotsubo event(s) including physician records and all relevant imaging. Participants will also be asked quality of life questionnaires and will be followed every 4 months for events.

03

Conditions studied

  • Takotsubo Cardiomyopathy
  • Broken Heart Syndrome
  • Tako-tsubo Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with history of takotsubo syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician diagnosis of takotsubo syndrome
  • Age>18 years

Exclusion criteria

Exclusion Criteria:

- Lack of capacity to provide

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiac Events

    Medical record review and patient report of repeat takotsubo event, MI, heart failure, unstable angina, chest pain ER visit, cardiovascular death, stroke

    Time frame: up to 10 years

Secondary outcomes

  1. Quality of life assessed using the Patient Reported Outcome Measurement Information System (PROMIS-10) questionnaire

    Measure of quality of life

    Time frame: every four months up to 10 years

  2. Anxiety is assessed using the Hospital Anxiety and Depression Scale (HADS-A)

    Measure of anxiety

    Time frame: every four months up to 10 years

  3. Depression assessed using the Patient Health Questionnaire (PHQ-9)

    Measure of depression

    Time frame: every four months up to 10 years

  4. Perceived stress is measured using the Perceived Stress Scale (PSS-10)

    Measure of perceived stress

    Time frame: every four months up to 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2009 (actual). Primary completion is estimated for Sep 2028, 227 months after the start.

Of 25 observational studies under Takotsubo Cardiomyopathy, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 40. This study's planned 227 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2018
First posted
Sep 10, 2018
StartActual
Sep 11, 2009
Primary completionEst.
Sep 1, 2028
CompletionEst.
Aug 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: b•••@nyumc.org→H•••@nyulangone.org; b•••@nyumc.org→A•••@nyulangone.org. See the current contact
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Contact Study contact's phone or email changed: b•••@nyumc.org→H•••@nyulangone.org; b•••@nyumc.org→A•••@nyulangone.org. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03663348
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Sep 11, 2009
Primary completion
Sep 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Harmony Reynolds, MD
Contact
Harmony.Reynolds@nyulangone.org
Anais Hausvater, MD
Contact
Anais.Hausvater@nyulangone.org

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion